In summary, GLP-1RA overcomes the metabolic shortcomings of endogenous GLP-1 through structural modification[119], and with a “glucose concentration-dependent” precise regulatory mode, achieves multi-dimensional intervention in the pathological links of T2DM (insulin resistance, β-cell decline, glucose metabolism imbalance), while having effects such as weight loss and organ protection, completely reshaping the treatment pattern of T2DM. This evidence concerns the gene GCG and Insulin resistance.